{
    "organizations": [],
    "uuid": "806aa730aea58bd6e4c5f956e92e65595f69b986",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aptevo-therapeutics-begins-patient/brief-aptevo-therapeutics-begins-patient-dosing-in-phase-2-clinical-trial-of-otlertuzumab-in-peripheral-t-cell-lymphoma-idUSASB0C04R",
    "ord_in_thread": 0,
    "title": "BRIEF-Aptevo Therapeutics Begins Patient Dosing In Phase 2 Clinical Trial Of Otlertuzumab In Peripheral T-Cell Lymphoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Aptevo Therapeutics Inc:\n* APTEVO THERAPEUTICS BEGINS PATIENT DOSING IN PHASE 2 CLINICAL TRIAL OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T22:10:00.000+02:00",
    "crawled": "2018-01-09T17:03:31.064+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "aptevo",
        "therapeutic",
        "inc",
        "aptevo",
        "therapeutic",
        "begin",
        "patient",
        "dosing",
        "phase",
        "clinical",
        "trial",
        "otlertuzumab",
        "peripheral",
        "lymphoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}